Real-World Evidence of Option Value in Metastatic Melanoma

Author(s)

Wong W1, To TM2, Li M3, Lee W4, Veenstra D5, Garrison LP5
1Genentech, South San Francisco, CA, USA, 2Genentech, Inc., South San Francisco, CA, USA, 3The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 4University of Washington, Pasadena, CA, USA, 5University of Washington, Seattle, WA, USA

OBJECTIVES : There is little real-world evidence of realized real option value (ROV) - the value a drug provides by extending survival to receive benefits from future innovations. This analysis aims to measure ROV with real-world clinical outcomes data, using ipilimumab in metastatic melanoma (mM).

METHODS : We conducted a retrospective analysis using the nationwide Flatiron Health electronic health record-derived de-identified database. Patients with mM initiating treatment before 4/19/15 (1st line (1L) pembrolizumab data available) were included in the study. The next innovation date was defined as 9/4/2014 (the FDA approval date for 2nd line (2L) pembrolizumab). We estimated proportions of patients surviving to the next innovation date and receiving a cancer immunotherapy (CIT). Inverse probability of treatment weighted Kaplan-Meier estimates for real-world overall survival (OS) were estimated by treatment cohorts (Ipilimumab followed by CIT or no CIT) and line of therapy. Observed ROV was estimated using truncated mean OS and proportions in each treatment cohort.

RESULTS : Among 721 mM patients, 50% of 1L ipilimumab users and 18% of 1L chemotherapy users survived to the next innovation date. Among survivors to the next innovation date, 45% (1L Ipilimumab), 26% (1L chemotherapy), 52% (2L Ipilimumab), and 50% (2L Chemotherapy) received CITs. Mean OS for ipilimumab followed by a CIT was 38.3 months (1L) and 38.9 months (2L), while those who didn’t receive a CIT was 21.7 months (1L) and 13.9 months (2L). Estimated ROV for ipilimumab was an additional 3.7 months survival (32.2% of conventional value) in 1L, and 5.1 months (60% of conventional value) in 2L ipilimumab, and 4.0 months across lines of therapy.

CONCLUSIONS : This study provides real-world evidence of clinically meaningful ROV and may support consideration of ROV when assessing the value of life-extending drugs in areas with likely future innovation.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)

Acceptance Code

RW2

Topic

Clinical Outcomes, Economic Evaluation

Topic Subcategory

Clinical Outcomes Assessment, Novel & Social Elements of Value

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×